Impairing proliferation of glioblastoma multiforme with CD44+ selective conjugated polymer nanoparticles.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
15 07 2022
15 07 2022
Historique:
received:
15
03
2022
accepted:
21
06
2022
entrez:
15
7
2022
pubmed:
16
7
2022
medline:
20
7
2022
Statut:
epublish
Résumé
Glioblastoma is one of the most aggressive types of cancer with success of therapy being hampered by the existence of treatment resistant populations of stem-like Tumour Initiating Cells (TICs) and poor blood-brain barrier drug penetration. Therapies capable of effectively targeting the TIC population are in high demand. Here, we synthesize spherical diketopyrrolopyrrole-based Conjugated Polymer Nanoparticles (CPNs) with an average diameter of 109 nm. CPNs were designed to include fluorescein-conjugated Hyaluronic Acid (HA), a ligand for the CD44 receptor present on one population of TICs. We demonstrate blood-brain barrier permeability of this system and concentration and cell cycle phase-dependent selective uptake of HA-CPNs in CD44 positive GBM-patient derived cultures. Interestingly, we found that uptake alone regulated the levels and signaling activity of the CD44 receptor, decreasing stemness, invasive properties and proliferation of the CD44-TIC populations in vitro and in a patient-derived xenograft zebrafish model. This work proposes a novel, CPN- based, and surface moiety-driven selective way of targeting of TIC populations in brain cancer.
Identifiants
pubmed: 35840697
doi: 10.1038/s41598-022-15244-0
pii: 10.1038/s41598-022-15244-0
pmc: PMC9287456
doi:
Substances chimiques
CD44 protein, human
0
Hyaluronan Receptors
0
Polymers
0
Hyaluronic Acid
9004-61-9
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
12078Subventions
Organisme : CIHR
ID : 406811
Pays : Canada
Informations de copyright
© 2022. The Author(s).
Références
Drug Deliv. 2018 Nov;25(1):388-397
pubmed: 29378465
Proc Natl Acad Sci U S A. 2020 May 26;117(21):11432-11443
pubmed: 32381732
Expert Opin Investig Drugs. 2009 Aug;18(8):1061-83
pubmed: 19555299
Drug Deliv. 2019 Dec;26(1):551-565
pubmed: 31928355
J Biol Chem. 2012 Jun 1;287(23):18995-9007
pubmed: 22433859
Mater Sci Eng C Mater Biol Appl. 2017 Jan 1;70(Pt 1):889-896
pubmed: 27770966
Brain Res Bull. 2008 Mar 28;75(5):619-28
pubmed: 18355638
Stem Cells Int. 2019 Mar 7;2019:2617030
pubmed: 30984267
Cell Stem Cell. 2014 Mar 6;14(3):357-69
pubmed: 24607407
Nat Commun. 2017 Sep 7;8(1):470
pubmed: 28883395
Nanomedicine. 2015 Nov;11(8):1883-92
pubmed: 26238079
Nat Commun. 2019 Apr 16;10(1):1787
pubmed: 30992437
Dev Biol. 2020 Jan 15;457(2):181-190
pubmed: 30862465
Biomaterials. 2014 Apr;35(13):4133-45
pubmed: 24529623
Biosci Rep. 2020 Apr 30;40(4):
pubmed: 32232385
Nat Commun. 2020 Jan 2;11(1):32
pubmed: 31896744
Carbohydr Polym. 2017 Feb 10;157:419-428
pubmed: 27987946
Chem Phys Lipids. 1993 Sep;64(1-3):3-18
pubmed: 8242840
Brain. 2019 Apr 1;142(4):847-866
pubmed: 30946477
Nat Commun. 2019 May 28;10(1):2341
pubmed: 31138801
Oncotarget. 2018 Jun 19;9(47):28421-28433
pubmed: 29983870
ACS Nano. 2015 Feb 24;9(2):1581-91
pubmed: 25558928
Nanomedicine (Lond). 2017 Oct;12(20):2533-2554
pubmed: 28952878
Cell Rep. 2017 Aug 15;20(7):1641-1653
pubmed: 28813675
Stem Cells. 2013 May;31(5):857-69
pubmed: 23307586
Biomacromolecules. 2017 Oct 9;18(10):3040-3051
pubmed: 28858529
Sci Rep. 2018 Mar 15;8(1):4608
pubmed: 29545552
Oncogene. 1999 Feb 18;18(7):1435-46
pubmed: 10050880
Cancer Res. 2007 May 1;67(9):4010-5
pubmed: 17483311
J Control Release. 2015 Dec 28;220(Pt A):275-286
pubmed: 26518722
Nanotechnology. 2016 Feb 12;27(6):065103
pubmed: 26754042
Chem Commun (Camb). 2020 Jan 23;56(7):1093-1096
pubmed: 31894764
Nat Rev Cancer. 2020 Jan;20(1):26-41
pubmed: 31601988
ACS Nano. 2013 Nov 26;7(11):9518-25
pubmed: 24274814
Nat Nanotechnol. 2014 Mar;9(3):233-9
pubmed: 24463363
Nat Nanotechnol. 2011 Nov 06;7(1):62-8
pubmed: 22056728
Cancer Manag Res. 2020 Feb 03;12:769-775
pubmed: 32099472
Int J Pharm. 2020 Nov 15;589:119817
pubmed: 32866646
Clin Cancer Res. 2008 Mar 15;14(6):1804-13
pubmed: 18347183
Sci Rep. 2019 Jan 29;9(1):900
pubmed: 30696847
Nat Cell Biol. 2016 Dec;18(12):1336-1345
pubmed: 27820599
ACS Appl Mater Interfaces. 2015 Dec 23;7(50):27885-99
pubmed: 26619329
Adv Healthc Mater. 2019 May;8(10):e1900047
pubmed: 30920772
Sci Rep. 2019 Jun 19;9(1):8802
pubmed: 31217424
Genes Dev. 2019 Jun 1;33(11-12):591-609
pubmed: 31160393
ACS Nano. 2017 Oct 24;11(10):10124-10134
pubmed: 28892609
Drug Discov Today. 2008 Dec;13(23-24):1099-106
pubmed: 18848640
Biomacromolecules. 2014 Jun 9;15(6):1955-69
pubmed: 24798476
Cell Commun Signal. 2019 Jul 22;17(1):80
pubmed: 31331331
Nat Commun. 2020 Sep 16;11(1):4660
pubmed: 32938908
Biochem Biophys Res Commun. 1994 Jul 29;202(2):673-9
pubmed: 8048936
J Control Release. 2020 Dec 10;328:679-695
pubmed: 32979453
Genes Dev. 2018 Apr 1;32(7-8):466-478
pubmed: 29692355
Chem Soc Rev. 2017 Jul 17;46(14):4218-4244
pubmed: 28585944
Front Oncol. 2018 Oct 23;8:462
pubmed: 30406029
J Nanopart Res. 2017;19(3):117
pubmed: 28367070
Cell Rep. 2017 Jan 3;18(1):23-31
pubmed: 28052252
Biomaterials. 2019 Sep;216:119252
pubmed: 31212086
Chem Commun (Camb). 2010 Mar 14;46(10):1617-9
pubmed: 20177593
Exp Cell Res. 2015 Mar 1;332(1):89-101
pubmed: 25597427
Adv Mater. 2019 Aug;31(34):e1803549
pubmed: 30773699